# Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer

> **NCT06916494** · PHASE1 · RECRUITING · sponsor: **First Affiliated Hospital of Chongqing Medical University** · enrollment: 10 (estimated)

## Conditions studied

- Muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** Rutin
- **DRUG:** Gemcitabine, Cisplatin
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT06916494
- **Lead sponsor:** First Affiliated Hospital of Chongqing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2026-01-20
- **Final completion:** 2026-01-20
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06916494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06916494, "Pilot Study on Rutin Combined With Tislelizumab and GC (Gemcitabine and Cisplatin) as Neoadjuvant Therapy for Platinum-refractory Muscle-invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06916494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*